Clinical trials
NEC clinical trials
Below are recruiting nec clinical trials, each written for real people, not researchers. We’re tracking 31 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
St Louis, MissouriAges 18 years+ - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Tampa, FloridaAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT07416695RecruitingPhase 1
Study of HLX3901 for advanced lung or neuroendocrine cancer
This trial tests a new drug, HLX3901, for people with advanced small cell lung cancer or neuroendocrine cancer that has worsened after previous treatments. The goal is to see if it's safe and how the body handles it.
BeijingAges 18–75 - NCT07191678Recruiting
Gut health in preterm babies receiving blood transfusions
This study looks at how different types of feeding affect the gut of very preterm babies when they receive a blood transfusion. If your baby qualifies, the team will do extra monitoring and ultrasound scans to learn more about gut health during transfusions.
LondonAges 5 months–7 months - NCT07016230RecruitingPhase 2
Study of tarlatamab for small-cell lung cancer and other neuroendocrine cancers
This trial tests a new drug, tarlatamab, which targets a protein called DLL3 found on the surface of certain cancer cells. The goal is to see if it can shrink or control tumors in people with small-cell lung cancer or other poorly differentiated neuroendocrine cancers, and to learn more about who benefits most.
BordeauxAges 18 years+ - NCT06727877Recruiting
Predicting bowel disease in premature babies using gut bacteria
This study looks at the gut bacteria of premature babies to see if changes can predict a serious bowel condition (ulcero-necrotizing enterocolitis). It aims to use artificial intelligence to help doctors catch it early.
Clermont-FerrandAges Up to 1 day - NCT05636397Recruiting
Oral L-citrulline for fragile preterm babies with lung or bowel disease
This trial studies whether an oral medicine called L-citrulline (L-cit) is safe and how it works in very preterm infants. It includes two groups: babies with chronic lung disease (with or without high blood pressure in the lungs) and babies recovering from severe bowel infection (NEC).
Toronto, OntarioAges 1 month–6 months - NCT04732546Recruiting
Study of reproductive health in women with uterine variations
This study looks at how certain uterine (womb) variations affect diagnosis, treatment choices, and reproductive outcomes. It may help doctors better understand these conditions and improve care for affected women.
Ghent, East FlandersAges Up to 45 years - NCT06393816RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC lung cancer
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Aix-en-ProvenceAges 18 years+ - NCT07699666Recruiting
Cord clamping timing for preterm babies
This study compares waiting a bit before clamping the umbilical cord versus clamping it right away for babies born between 32 and 37 weeks of pregnancy. It helps determine which approach may be better for preterm infants.
Tunis, Tunis GovernorateAges birth+ - NCT06701396RecruitingPhase 3
Tasimelteon for delayed sleep phase disorder with genetic variant
This study tests a new sleep medication called tasimelteon compared to a placebo (inactive treatment) for people with a specific sleep disorder linked to a genetic change in the body's internal clock. If you have Delayed Sleep-Wake Phase Disorder and carry the CRY1Δ11 variant, this trial may help improve your sleep timing.
Çankaya, AnkaraAges 18–75 - NCT07544654RecruitingPhase 3
Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Scottsdale, ArizonaAges 18 years+ - NCT06454461Recruiting
Testing upadacitinib for stable vitiligo
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
Changchun, JilinAges 18–60 - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT05165407RecruitingPhase 2
Study drugs for advanced high-grade neuroendocrine tumors
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07192393Recruiting
Impact of early birth and NEC on family life and finances
This study looks at how having a very early baby (before 30 weeks) and a serious bowel problem called NEC affects your family's quality of life and finances. Parents will share their experiences through surveys.
Norwich, NorfolkAges Up to 7 months - NCT06978855Enrolling by invitation
Acupressure bands for better sleep in medical trainees
This study tests if wearing a wrist acupressure band at night can improve sleep quality. It's for medical students and doctors in training at AUB who are not using sleep aids or alcohol daily.
Beirut, BeirutAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06937905RecruitingPhase 3
Tarlatamab vs chemo for advanced NEC after one prior treatment
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
AngersAges 18 years+ - NCT06893783RecruitingPhase 2
Tarlatamab for advanced extrapulmonary neuroendocrine carcinoma
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT06889493RecruitingPhase 1
SVV-001 plus immunotherapy for neuroendocrine cancers
This trial tests a new virus-based treatment (SVV-001) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced neuroendocrine cancers that have gotten worse after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Miami, FloridaAges 18 years+ - NCT06681129Recruiting
Study of normal gut development in newborns
This study looks at how the intestines grow and develop in both premature and full-term babies. It involves collecting small tissue samples during a baby's already-planned surgery or scope procedure to better understand normal development and digestive diseases.
Boston, MassachusettsAges Up to 2 years - NCT06631092RecruitingPhase 1/Phase 2
Personalized cancer vaccine with standard therapy for triple-negative breast cancer
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
ErlangenAges 18 years+
Hear when a new NEC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nec?
- Yes. Clin2 currently lists 31 recruiting nec studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nec trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nec trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.